drugset / Trial / NCT00048061

MOBILE Study - A Study of Bonviva (Ibandronate) Regimens in Women With Post-Menopausal Osteoporosis

NCT00048061

Phase 3 Completed 1609 enrolled Hoffmann-La Roche
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will compare the efficacy and safety of different treatment regimens of oral Bonviva tablets in women with post-menopausal osteoporosis. Patients will also receive daily supplementation with vitamin D and calcium. The anticipated time of study treatment is 2+ years, and the target sample size is 500+ individuals.

Timeline

Start
2002-04
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibandronate Other / unclassified 2.5 mg Oral
Subject Ibandronate Other / unclassified 100 mg Oral
Subject Ibandronate Other / unclassified 150 mg Oral